Théa Pharma Ireland

Company snapshot

Théa Pharma Ireland is the Irish subsidiary of Laboratoires Théa, Europe’s leading and most innovative eye health group, founded in 1994 by Henri Chibret. The Chibret family has been devoted to ophthalmology for over 150 years, driven by one simple purpose — to help people see life better. Théa was the pioneer and remains the world leader in preservative-free eye care, a breakthrough that transfor

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Théa Pharma Ireland. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Théa Pharma Ireland.

1. Jun 8, 2026 Clinical update

   PASSION — Phase 2

2. Jun 8, 2026 Clinical update

   GR-2021-12373041 — Approved

3. Jun 8, 2026 Clinical update

   CRCFC-TEICO.SA.2022 — Phase 2

4. Jun 8, 2026 Clinical update

   SIPO20 — Approved

5. Jun 8, 2026 Clinical update

   SAVE PAIN 2025 — Phase 3

View all clinical trial activity →

• What is Théa Pharma Ireland?

  Verona Pharma Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include cystic fibrosis, Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive), multifocal spasticity of the upper and lower limb due to cerebral palsy, Gastric

• Is Théa Pharma Ireland publicly traded?

  Théa Pharma Ireland appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Théa Pharma Ireland develop or market?

  We link 42 drug profile(s) where Théa Pharma Ireland is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/verona-pharma-ireland-limited#company-drugs.

• What are the latest developments for Théa Pharma Ireland?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Théa Pharma Ireland focus on?

  Théa Pharma Ireland focuses on cystic fibrosis, Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive), multifocal spasticity of the upper and lower limb due to cerebral palsy based on our analysis of their pipeline programs and drug development activities.